

Curriculum Vitae

Name	Valerie Chew Suk Peng	
Current Position & Affiliation	Principal Investigator (Translational Immunology Institute (TII), SingHealth-DukeNUS) Assistant Professor (Duke-NUS Medical School)	
Country	Singapore	

Educational Background

2004-2008

- Doctor of Philosophy- Immunology (Integrative Sciences & Engineering), National University of Singapore (NUS)

1999-2003

- Bachelor of Science (Pharmacy), First class honours, NUS.

Professional Experience

2016-present

- Principal Investigator, Translational Immunology Institute (TII)

2015-present

- Adjunct Assistant Professor Duke-NUS Medical School

2015- 2016

- Senior Research Scientist, Translational Immunology Institute (TII)

2007- 2014

- Research Fellow-Scientist, Singapore Immunology Network (SIgN) A*Star

Professional Organizations

Committee member for the following societies:

2017-present

- i) Singapore Society for Immunology (SgSI)
- ii) Singapore Society of Oncology (SSO) and
- iii) The EUREKA Institute for Translational Medicine.

Main Scientific Publications

1. P. Nguyen, S. Ma et al P. Chow, W. Zhai and **V Chew**. Intratumoural immune heterogeneity as a hallmark of tumour evolution and progression in hepatocellular carcinoma. *Nature Com.* **12**, 227 (2021). (IF: 12.121)
2. YH Lee, D Tai, C Yip, SP Choo and **V Chew**. Combinational immunotherapy for Hepatocellular carcinoma (HCC): Radiotherapy, immune checkpoint blockade and beyond. *Frontiers in immunology.* (2020) Sep 30;11:568759. doi: 10.3389/fimmu.2020.568759. (IF: 5.085)
3. S Chuah and **V Chew**. High-dimensional immune-profiling in cancer- implications for immunotherapy. *Journal for ImmunoTherapy of Cancer (JITC)* (2020);8:e000363. doi: 10.1136/jitc-2019-000363. (IF: 9.913)
4. D Tai, SP Choo and **V Chew**. Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers. *Cancers* (2019), 11(12), 1926. (IF: 6.126)
5. CJ Lim, YH Lee, et al. **V Chew**. Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma. *Gut.* (2019) May;68(5):916-927 (IF: 19.819)
6. **V Chew**, YH Lee, et al. Immune activation underlies a sustained clinical response to Yttrium-90 radioembolisation in hepatocellular carcinoma. *Gut* (2019), 68(2): 335-346. (IF: 19.819)
7. **V Chew**, L Lai, L Pan, CJ Lim, et al. Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses. *Proceedings of the National Academy of Sciences*, (2017), 114(29): E5900-E5909. (IF: 9.58)
8. M Garnelo, A Tan, et al. **V Chew**. Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma. *Gut* (2017), 66(2): 342-351. (IF: 19.819)
9. Bard-Chapeau EA, Nguyen AT, Rust AG, et al. **Chew V**, et al. Transposon mutagenesis identifies genes driving hepatocellular carcinoma in a chronic hepatitis B mouse model. *Nature genetics* (2014), 46(1): 24. (IF: 27.603)
10. **Chew V**, Tow C, Bard-Chapeau E, Copeland N, Jenkins N et al. Toll-like Receptor 3-Expressing Tumor Parenchyma and Infiltrating Natural Killer Cells in Hepatocellular Carcinoma Patients. *J Natl Cancer Inst.* (2012);104 (23):1796-80. (IF: 12.589)
11. **V Chew**, HC Toh, JP Abastado. Immune microenvironment in tumor progression: characteristics and challenges for therapy. *Journal of oncology*, (2012): 608406 (IF: 2.206)

12. **Chew V**, Chen JM, Lee DM, et al. Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma. *Gut* (2012); 61(3):427-38. (IF: 19.819)
 13. **Chew V**, Tow C, Teo M, et al. Inflammatory tumor microenvironment is associated with superior survival in hepatocellular carcinoma patients. *Journal of hepatology* (2010), 52(3): 370-379. (IF: 20.582)
-